AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceHealth Care
Boronic AcidsPyrazinesInjectionsProteasome InhibitorsMultiple MyelomaProtease InhibitorsAntineoplastic AgentsProteasome Endopeptidase ComplexInjections, IntravenousInjections, IntramuscularThalidomideDrug SynergismCell Line, TumorInjections, IntralesionalInjections, SubcutaneousInjections, Intra-ArticularApoptosisAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneDrug Resistance, NeoplasmLymphoma, Mantle-CellInjections, IntraperitonealDose-Response Relationship, DrugTreatment OutcomeXenograft Model Antitumor AssaysInjections, IntradermalInjections, EpiduralInjections, IntraventricularMaximum Tolerated DoseInjections, Intra-ArterialTime FactorsDrug Administration ScheduleIntravitreal InjectionsInjections, SpinalMaintenance ChemotherapyInjections, JetMelphalanRecurrenceInjections, IntraocularPeripheral Nervous System DiseasesNF-kappa BMice, SCIDDisease Models, AnimalCell ProliferationRats, Sprague-DawleyLactate DehydrogenasesDoxorubicinCell SurvivalHydroxamic AcidsMice, NudeFlow Injection AnalysisMicroinjectionsDrug Screening Assays, AntitumorMice, Inbred C57BLLeukemia, Plasma CellProto-Oncogene Proteins c-bcl-2Waldenstrom MacroglobulinemiaMice, Inbred BALB CInduction ChemotherapyPerillaStem Cell TransplantationSubstance Abuse, IntravenousAntibodies, Monoclonal, Murine-DerivedSalvage TherapyMyeloid Cell Leukemia Sequence 1 ProteinBlotting, WesternSperm Injections, IntracytoplasmicLeupeptinsTumor Cells, CulturedNeoplasms1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium SaltPrednisoneUnfolded Protein ResponseThiostreptonTNF-Related Apoptosis-Inducing LigandSyringesTransplantation, AutologousDisease-Free SurvivalCaspasesAntibodies, MonoclonalDeath Domain Receptor Signaling Adaptor ProteinsNeedlesRats, WistarSignal TransductionDown-RegulationCell DeathPlasma CellsImmunohistochemistryRNA, Small InterferingReceptors, Death DomainNeoplasm Recurrence, LocalTissue DistributionNeoplasm TransplantationHematologic DiseasesSurvival RateAnesthetics, LocalLiverVitreous BodyFlow CytometryTriamcinolone Acetonide
Multiple myelomaCombinationTreatmentProteasome inhibitorMultiple MyelomaIntravenousAdministerCareful risk-benefit assessmentDiscontinueInfusionPatientsTherapy
Multiple myeloma1
Combination1
  • The usual dose is 1.3 mg/m2 administered over 3-5 seconds by rapid intravenous or subcutaneous injection in combination with oral melphalan and prednisone for nine 6-week treatment cycles. (indiangenericprice.com)
Treatment1
  • Receiving subcutaneous injections of treatment at home, where facilitated by the health system. (mpeurope.org)
Proteasome inhibitor1
  • GLASGOW - Patients with multiple myeloma are able to self-administer the proteasome inhibitor bortezomib ( Velcade , Takedo Oncology) at home via subcutaneous injections, potentially improving quality of life and reducing healthcare resource utilisation, argue UK researchers. (medscape.com)
Multiple Myeloma2
  • Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. (nih.gov)
  • In 2011, the National Institute for Health and Care Excellence (NICE) recommended bortezomib, combined with an alkylating agent and a corticosteroid, as an option for the first-line treatment of multiple myeloma. (medscape.com)
Intravenous2
  • In 2011, Prof Philippe Moreau and colleagues published data showing that giving bortezomib subcutaneously is not only non-inferior to standard intravenous administration in terms of efficacy but also had an improved safety profile. (medscape.com)
  • The recommended starting dose of Bortezomib Injection is 1.3 mg/m 2 administered as a 3 to 5 second bolus intravenous injection. (nih.gov)
Administer4
  • Do not administer bortezomib for injection by any other route. (nih.gov)
  • To address this, the team decided to explore whether they could help patients to be able to self-administer bortezomib at home. (medscape.com)
  • Administer doxorubicin hydrochloride liposome injection at an initial rate of 1 mg/min to minimize the risk of infusion reactions. (nih.gov)
  • Do not administer as bolus injection or undiluted solution ( 2 ). (nih.gov)
Careful risk-benefit assessment1
  • 2.7 ) Patients with pre-existing severe neuropathy should be treated with bortezomib only after careful risk-benefit assessment. (nih.gov)
Discontinue2
  • discontinue bortezomib if suspected. (nih.gov)
  • Discontinue doxorubicin hydrochloride liposome injection infusion for serious or life-threatening infusion-related reactions ( 5.2 ). (nih.gov)
Infusion3
  • Withhold doxorubicin hydrochloride liposome injection for infusion-related reactions and resume at a reduced rate. (nih.gov)
  • Serious, life-threatening, and fatal infusion-related reactions can occur with doxorubicin hydrochloride liposome injection. (nih.gov)
  • In order to avoid visits to the hospital by belatacept-treated kidney transplant recipients (KTRs) during the initial period of the pandemic, we promptly converted 176 KTRs at two French transplant centers from once-monthly 5 mg/kg in-hospital belatacept infusion to once-weekly 125 mg subcutaneous abatacept injection. (bvsalud.org)
Patients8
  • Patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions. (nih.gov)
  • Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma. (nih.gov)
  • Tanya Burton, a myeloma clinical nurse specialist at the University Hospital of Wales, Cardiff, and colleagues devised a plan for self-administration of the drug after seeing how much time their patients spent waiting at their clinic for a simple injection. (medscape.com)
  • Working with the pharmacy department to establish the safety of the drug for taking home, and developing a care plan with physicians and the nursing team, they instructed patients on how to self-inject and deal safely with the equipment. (medscape.com)
  • This will allow them to offer the option of self-administration to almost all the patients in their clinic currently treated with bortezomib, as they will be able to take home a month's worth of treatments. (medscape.com)
  • In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ). (nih.gov)
  • Doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. (nih.gov)
  • The data showed that experienced surgeons can safely perform taTME in these patients. (medivizor.com)
Therapy2
  • Monitor closely for new or worsening symptoms and consider interrupting bortezomib therapy. (nih.gov)
  • Interrupt bortezomib therapy to assess reversibility. (nih.gov)